For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide derived from bovine brain cortex extract (Cortexin), developed by Vladimir Khavinson's group in St. Petersburg. It is proposed to remodel chromatin and reactivate silenced genes in neural and cardiac tissue. Rat studies show 27% faster nerve fiber growth and 40% higher conduction velocity after sciatic nerve transection. No published, peer-reviewed human clinical trial exists. A 2004 background-section claim of human therapeutic use has no primary citation and cannot be treated as clinical evidence. This is a Tier 4 compound.
There are zero published, peer-reviewed, controlled human clinical trials of Cortagen. Every significant quantitative finding in this profile comes from rat or mouse models. One 2004 microarray paper (Anisimov et al., Neuroendocrinology Letters) states in its background section that "in humans, Cortagen demonstrated a pronounced therapeutic effect upon the structural and functional posttraumatic recovery of peripheral nerve tissue" but this claim cites no primary source and no human trial data appear anywhere in the indexed literature. The Signal searched PubMed, Semantic Scholar, and ResearchGate. No controlled human study was found. This background-section claim should not be treated as clinical evidence.
Cortagen is part of the Khavinson bioregulator family, developed at the St. Petersburg Institute of Bioregulation and Gerontology. The research base is almost entirely single-laboratory, with Prof. Vladimir Khavinson as author or co-author on the majority of publications. This limits independent replication and raises standard concerns about investigator bias. None of the animal studies are blinded or powered to detect specific effect sizes with modern rigor.
Cortagen should not be confused with Cortexin, the bovine polypeptide preparation from which it was derived. Cortexin contains hundreds of peptides and has a larger (though still limited) clinical evidence base in Russian neurological practice. Cortagen is a single synthetic tetrapeptide selected as a candidate active fraction, a hypothesis about mechanism rather than proven equivalence to the parent preparation.
Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide derived through directed amino acid analysis of Cortexin, a polypeptide extract of bovine brain cortex developed in Soviet-era Russia during the 1980s. The goal was to identify short peptide sequences responsible for Cortexin's observed neurotrophic properties and synthesize them chemically, bypassing the regulatory and supply complications of animal-derived preparations.
The Khavinson program at the Institute of Bioregulation and Gerontology produced a family of tissue-specific short peptides following this template: identify a natural tissue extract with biological activity, determine its amino acid composition, synthesize short candidate sequences, and test them against the parent extract. Other members include Epithalon (pineal gland), Thymalin (thymus), and Vilon (also thymus-derived). Each is assigned to a tissue of origin that supposedly confers target selectivity.
For Cortagen, the tissue of origin is the cerebral cortex and the claimed selectivity is for CNS and peripheral nervous system targets. The research program spans approximately 25 years of publications, mostly in Russian-language journals or their English-translation counterparts: Bulletin of Experimental Biology and Medicine, Doklady Biological Sciences, and Advances in Gerontology.
Cortagen's proposed primary mechanism is chromatin remodeling through heterochromatin decondensation. With aging, gene-regulatory regions of DNA become increasingly compacted into transcriptionally silent heterochromatin, reducing expression of proteins involved in cellular maintenance and repair. Khavinson's group proposes that short peptides like Cortagen interact directly with DNA promoter regions via complementary binding, loosening this compaction and reactivating silenced gene sets.
The 2004 microarray study (Anisimov, Khavinson, Anisimov, Neuroendocrinology Letters 25:87-93) quantified this in female CBA mouse hearts: a single course of Cortagen significantly altered expression of 110 genes across 234 DNA regions out of more than 15,000 assessed. Upregulated targets included Hsc70 (heat shock protein with myocardial protective roles), ribosomal structural components, and genes in stress-response and repair categories. Downregulated targets included pro-inflammatory and pro-fibrotic regulators. The pattern broadly resembles other Khavinson peptides but shows compound-specific effects distinct from Epithalon or Vilon, supporting some degree of sequence selectivity even at the four-amino-acid level.
In neural tissue, the proposed downstream effects of chromatin remodeling include upregulation of neurotrophic factor synthesis, enhanced expression of cytoskeletal proteins needed for axonal growth, and improved ribosomal activity in neurons. These are inferred from the gene expression work done in heart tissue, not directly measured in nerve regeneration studies.
A second mechanism involves antioxidant pathway modulation. Rat ischemia studies showed Cortagen co-administered with Cortexin reduced lipid peroxidation products in brain tissue and preserved superoxide dismutase activity versus ischemic controls. In immune cell studies, Cortagen activated interleukin-2 mRNA synthesis in mouse splenocytes in vitro without exogenous stimulation, suggesting immunomodulatory effects at the transcriptional level. Electrophysiology studies also show Cortagen hyperpolarizes neurons and reduces spontaneous firing rates in vitro, interpreted as a membrane-stabilizing neuroprotective effect.
At early timepoints following sciatic nerve transection and surgical repair in rats, intramuscular Cortagen at 10 mcg/kg for 10 days increased nerve fiber growth rate by 27% and conduction velocity by 40% versus untreated controls.
Five-month follow-up (Kolosova 2002) showed persistent improvement in functional restoration of the injured nerve. However, compound action potential conduction velocity through the suture site was not significantly different from controls at the late timepoint, suggesting the primary benefit is acceleration of early growth rather than normalization of mature conduction across the injury site.
The most consistent quantitative data in the Cortagen literature. The 27-40% improvement in early nerve growth parameters is a substantial effect size for a rodent model. The follow-up finding of unchanged late conduction through the suture site is a meaningful limitation that tempers enthusiasm for full functional restoration. All data are in rats. No human nerve injury data exist.
In a rat chronic cerebral ischemia model (bilateral carotid artery stenosis), both Cortexin and Cortagen improved behavioral recovery on individual behavior paradigms in rats stratified by hypoxia resistance.
Both compounds reduced lipid peroxidation products in serum and brain tissue and preserved superoxide dismutase activity compared to ischemic controls. The authors concluded both compounds can increase efficacy of neuroprotective therapy in chronic brain ischemia.
Critical limitation: full-text in Russian only; available translated abstracts do not provide isolated Cortagen-specific effect sizes. Cortexin and Cortagen are reported in parallel rather than clearly separated in the conclusions available in translation.
Interesting antioxidant and behavioral data in a relevant ischemia model. The limitation is that Cortagen-specific effect sizes cannot be extracted from the available translated abstract. The study is also from the same research institution responsible for most Cortagen publications. Independent replication has not been published.
The 2004 microarray study found Cortagen altered expression of 110 of 15,341 assessed cardiac genes in CBA female mice, representing selective rather than broad transcriptional modulation. Upregulated genes included Hsc70 and ribosomal components; downregulated genes included pro-inflammatory regulators. Comparison with Epithalon and Vilon revealed compound-specific gene sets, supporting genuine sequence selectivity.
The 2014 Lezhava study demonstrated in vitro that Cortagen reversed heterochromatin condensation patterns in human lymphocytes from elderly donors toward patterns characteristic of younger cells. This is the closest the literature comes to a human biological effect, but it is a cell culture result, not a clinical finding.
The most mechanistically compelling data in the profile. Altering 110 genes selectively with a four-amino-acid peptide, and doing so differently from closely related peptides, suggests genuine biological specificity. The in vitro human lymphocyte chromatin data are hypothesis-generating but do not establish clinical anti-aging efficacy. No longevity endpoint study specific to Cortagen has been published.
Cortagen produced dose-dependent motor stimulation in CD-1 mice without anxiogenic effects in the elevated plus maze. Unlike Cortexin (which showed anxiolytic effects at acute dosing), Cortagen's primary behavioral effect was arousal/activation rather than anxiolysis.
A U-shaped dose-response was observed: 0.03 mg/kg produced stronger motor stimulation than 0.01 or 0.10 mg/kg. Authors attributed this to two overlapping biological processes with different active dose ranges. No memory or cognitive outcome measures were tested.
Cortagen and Cortexin diverge behaviorally despite sharing origins. Cortexin is anxiolytic; Cortagen is activating. The motor stimulation effect without anxiety induction is the kind of profile associated with antidepressant mechanisms (increased drive without agitation), but this is a speculative extrapolation from mouse motor behavior. No human mood or cognitive data exist.
The 2004 microarray study identified significant upregulation of Hsc70 (heat shock cognate protein 70, a key myocardial protective chaperone) and multiple cytoskeletal and metabolic genes in mouse cardiac tissue following Cortagen treatment. Pro-inflammatory and pro-fibrotic gene sets were downregulated.
These observations were made in healthy young mice, not in aged or diseased cardiac models. No Cortagen study in any cardiac disease model (MI, heart failure, arrhythmia) has been published. The 2004 background section references unspecified human cardiovascular effects alongside nerve recovery, but provides no primary citation.
Upregulating Hsc70 in cardiac tissue is mechanistically interesting given that heat shock protein insufficiency is associated with cardiac aging and ischemic vulnerability. But the data are from young healthy mice and provide no evidence of therapeutic benefit in any cardiac disease context. The uncited human claim in the background section cannot be used as evidence.
Khavinson bioregulator peptide. Limited data outside Russian literature.
All dosing data from animal studies. Community-sourced protocols circulate 1,000-2,000 mcg subcutaneous daily for 10-day courses. These are extrapolations from rat studies with no human PK validation. The Signal cannot endorse or contextualize these figures beyond noting their preclinical derivation.
Among Khavinson peptides, Cortagen occupies the narrowest clinical niche: peripheral nerve recovery and CNS neuroprotection. Semax has a more developed human evidence base in Russia, including registered clinical use for stroke, making it the stronger choice in the nootropic and neuroprotection space if clinical evidence matters. Epithalon has more direct published evidence for longevity endpoints in rodents. Cortagen's most specific claim, peripheral nerve regeneration, remains uncontested in its preclinical niche but awaits human translation.
No formal safety or pharmacokinetic studies in humans have been published for Cortagen. No human half-life, bioavailability, or clearance data exist in the indexed literature. The following reflects animal and in vitro observations only.
In rat nerve regeneration studies, intramuscular Cortagen at 10 mcg/kg for 10 days produced no reported adverse effects. In mouse behavioral studies, Cortagen at 0.01 to 0.10 mg/kg produced dose-dependent motor stimulation without anxiogenic effects. A complex U-shaped dose-response was observed in one mouse study, attributed to overlapping receptor systems with different active dose ranges. No toxicity endpoints were reported in any published study.
In avian models, Cortagen did not significantly affect erythrocyte counts, immune cell parameters, or hemostasis markers, contrasting with Epithalon which did modulate these parameters. This narrower biological footprint in hematopoietic systems is attributed to the C-terminal proline residue. No carcinogenicity, mutagenicity, or reproductive toxicity studies for Cortagen specifically have been published in accessible indexed literature.
The general argument that short endogenous-sequence peptides are safe because they mimic natural regulatory signals is mechanistically plausible but is not a substitute for formal human safety assessment. Extrapolating dosing from animal studies carries unquantifiable risk in the absence of human PK data.
Cortagen is a preclinical-stage compound with a coherent mechanistic hypothesis and a consistent, though modest and single-laboratory, body of animal data. The nerve regeneration findings (27% faster fiber growth, 40% higher conduction velocity in rats at 10 mcg/kg) are among the larger effect sizes in the Khavinson peptide literature and represent the most compelling signal in this profile.
The critical problem is the complete absence of published, peer-reviewed human clinical data. The 2004 claim of "pronounced therapeutic effect" in humans is unverified. It appears in a background section, cites no primary study, and is not supported by any indexed clinical report. Any human self-experimentation with Cortagen is occurring without PK data, safety data, or validated dosing.
The chromatin remodeling mechanism is biologically plausible and, if it operates in humans as proposed, would represent a genuinely novel approach to neural aging. But plausibility is not efficacy. The field needs an independent research group to publish controlled human or primate data before Cortagen can be considered for any evidence-based protocol. For now: a rat story with an interesting mechanism. Follow the literature. Do not confuse preclinical data with clinical evidence.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use